BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28695246)

  • 21. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
    Wu W; Chen X; Li N; Luo Q; Zou L
    Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
    Qi F; Chen B; Wang J; Lin X; Qi S; Yang J; Zhou S; Wang S; Gui L; Fang H; Liu P; Song Y; Yang S; Li Y; Dong M
    Leuk Lymphoma; 2019 Nov; 60(11):2679-2688. PubMed ID: 31298062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of patients treated with SVILE
    Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
    Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
    Tsai HJ; Lin SF; Chen CC; Chen TY; Su WC; Hwang WL; Lin JC; Chiou TJ; Kao WY; Chiu CF; Chang YF; Chang JS; Chang MC; Su IJ
    Eur J Haematol; 2015 Feb; 94(2):130-7. PubMed ID: 24957163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer/T-cell lymphoma.
    Sun P; Li Y; Li C; Ren K; Wang Y; Yang H; Jiang W; Zou L; Yang H; Zhou H; Li ZM
    Am J Hematol; 2023 Jul; 98(7):1043-1051. PubMed ID: 36970971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
    Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
    Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
    Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma.
    Huang Y; Jia B; Jiang S; Zhou S; Yang J; Liu P; Gui L; He X; Qin Y; Sun Y; Shi Y
    J Hematol Oncol; 2017 Jan; 10(1):7. PubMed ID: 28057019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
    Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
    Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
    Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
    Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
    Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.
    Jing XM; Zhang ZH; Wu P; Zhang SC; Ren YR; Xiong ZJ; Wei W; Luo L; Li L
    Leuk Res; 2016 Aug; 47():26-31. PubMed ID: 27239738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China.
    Chai Y; Chen B; Qi F; Fang H; Qi SN; Guo RY; Li N; Yang Y; Wang SL; Song YW; Yang JL; Zhang D; Wei YC; Li YX; Dong M
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):833-844. PubMed ID: 35452752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
    Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
    Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
    Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
    Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study.
    Liu T; Zhu F; Xiao Y; Li Q; Liu X; Yang K; Wu G; Zhang L
    Cancer Manag Res; 2018; 10():5061-5069. PubMed ID: 30464606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
    Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.